Inflammatory demyelinating polyradiculoneuropathy associated with membranous glomerulonephritis and thrombocytopaenia

Emsley, Hedley; Molloy, Jane

doi:10.1016/s0303-8467(02)00087-2

Cited by 19 publications

(19 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…GBS may be associated with NS, [2][3][4], whose age of onset ranges from 14 to 74 years with the majority of patients presenting between the fourth to sixth decade of life [9]. In this age group, membranous glomerulonephritis is the most common lesion responsible for NS and is the most reported abnormality in renal biopsy of patients with GBS and NS.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Relapsing Guillain Barré Syndrome and nephrotic syndrome secondary to focal segmental glomerulosclerosis

Souayah¹,

Cros

Stein

et al. 2008

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…The spectrum of renal manifestations in GBS ranged from asymptomatic proteinuria to overt nephrotic syndrome (NS) [2][3][4]. Most cases are related to membranous glomerulonephritis, although minimal changes disease, focal interstitial nephritis, and immune complex glomerulonephritis have been reported [5,6].…”

Section: Introductionmentioning

confidence: 99%

Relapsing Guillain Barré Syndrome and nephrotic syndrome secondary to focal segmental glomerulosclerosis

Souayah¹,

Cros

Stein

et al. 2008

Journal of the Neurological Sciences

View full text Add to dashboard Cite

“…Patients with GBS-like presentation who relapse shortly after treatment are classified as relapsing GBS (with treatment-related fluctuations), whereas those who deteriorate or relapse beyond 8 weeks from onset are classified as acute-onset CIDP [27]. Similar to those associated with membranous glomerulonephritis [9][10][11][12][13][14][15][16][17][18] and minimal change nephrotic syndrome [19][20][21][22], the neurologic presentations of previously reported cases of FSGS occurring in association with inflammatory neuropathies are diverse. These cases include patients with monophasic disease, like GBS [3,5,6], and those with a relapsing course, including CIDP [2,4,7,8] and relapsing GBS [1], suggesting heterogeneity in the time course and severity of neuropathy in these patients.…”

Section: Discussionmentioning

confidence: 99%

“…Their underlying glomerular pathologies include focal segmental glomerulosclerosis (FSGS) [1][2][3][4][5][6][7][8], membranous glomerulonephritis [9][10][11][12][13][14][15][16][17][18] and minimal change disease [19][20][21][22]. Here we describe a patient who synchronously developed acute-onset CIDP and FSGS, whose severe clinical manifestations were responsive to immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

Acute-onset chronic inflammatory demyelinating polyneuropathy with focal segmental glomerulosclerosis

Quek

Soon

Chan

et al. 2014

Journal of the Neurological Sciences

View full text Add to dashboard Cite

“…The published literature to date on the association of nephrotic syndrome in MS patients untreated with interferons is sparse. [10][11][12] There is, however, a relationship of other autoimmune diseases occurring in MS such as myasthenia gravis. [13][14] Cases have been reported both before interferon therapy was introduced and while interferons were being used.…”

Section: Discussionmentioning

confidence: 99%

Nephrotic Syndrome in a Multiple Sclerosis Patient Treated with Interferon β1a

Auty

Saleh

2005

Can. j. neurol. sci.

View full text Add to dashboard Cite

Europe and the Middle East. Interferon β1a is available worldwide as Avonex, given weekly as an intramuscular injection, and Rebif, which is given three times a week subcutaneously.The drugs are generally well-tolerated but side effects are common and include injection site reactions and flu-like symptoms. 4 Laboratory abnormalities are described and most commonly are lymphopenia, neutropenia, and raised liver transaminases.More recently there have been reports of more serious complications arising in the context of interferon therapy. It was ABSTRACT: Background: Interferon β has become standard therapy for reducing relapse frequency in relapsing/remitting Multiple Sclerosis (RRMS). Several different preparations are available including interferon β1a (Avonex, Rebif) and interferon β1b (Betaferon/Betaseron). For the most part these preparations have been considered safe. Recently there have been concerns relating to liver 1 and now kidney toxicity. Case Report: We present a case of a 28-yr old male who developed a severe case of nephrotic syndrome while being treated for relapsing/remitting Multiple Sclerosis (RRMS) with weekly injections of interferon β1a. Subsequent course: The nephrosis resolved almost completely once the interferon was stopped and after immunosuppressive treatment. At its peak the daily protein loss was 35.82 g. Kidney biopsy demonstrated membranous glomerulonephritis. Discussion: Two other case reports of nephrotic syndrome have been reported in the literature. This latest (third) report suggests that the safety profile should be reexamined and at least raises the question of potential renal toxicity of interferons in MS.RÉSUMÉ: Syndrome néphritique chez un patient atteint de sclérose en plaques traité par l'interféron β β1a. Introduction: L'interféron b est devenu le traitement standard pour diminuer la fréquence des récidives dans la sclérose en plaques récurrente/rémittente (SEPRR). Plusieurs préparations différentes sont disponibles dont l'interféron β1a (Avonex, Rebif) et l'interféron β1b (Betaferon/Betaseron). En général, on considérait que ces préparations étaient sûres. Depuis peu, on s'inquiète de leur toxicité hépatique et maintenant de leur toxicité rénale. Observation: Nous rapportons le cas d'un patient de 28 ans, originaire des Émirats arabes unis, qui a développé un syndrome néphritique aigu au cours du traitement de sa SEPRR au moyen d'injections hebdomadaires d'interféron b1a. Suivi: La néphrose a presque complètement disparu suite à l'arrêt du traitement et à un traitement immunosuppresseur. En phase aiguë, la perte quotidienne de protéines était de 35,82 g. La biopsie rénale a montré qu'il s'agissait d'une glomérulonéphrite membraneuse. Discussion: Deux autres cas de syndrome néphritique ont été rapportés dans la littérature. Ce troisième cas indique que le profil de sécurité des interférons devrait être réexaminé et soulève des questions concernant leur toxicité rénale chez les patients atteints de la SEP.

show abstract

Inflammatory demyelinating polyradiculoneuropathy associated with membranous glomerulonephritis and thrombocytopaenia

Cited by 19 publications

References 21 publications

Relapsing Guillain Barré Syndrome and nephrotic syndrome secondary to focal segmental glomerulosclerosis

Relapsing Guillain Barré Syndrome and nephrotic syndrome secondary to focal segmental glomerulosclerosis

Acute-onset chronic inflammatory demyelinating polyneuropathy with focal segmental glomerulosclerosis

Nephrotic Syndrome in a Multiple Sclerosis Patient Treated with Interferon β1a

Contact Info

Product

Resources

About